Objective: To compare changes in quality of life (QOL) that resulted from sublingual immunotherapy (SLIT) and subcutaneous immunotherapy (SCIT) in a real-world clinical setting.
A llergic rhinitis (AR) is a common problem that affects 20-40% of the U.S. population. 1 Although generally not considered a life-threatening problem, AR can adversely affect quality of life (QOL), including decreased productivity and sleep disturbance. 2, 3 Most individuals with AR are treated with medications designed to control symptoms, such as topical steroids and antihistamines, but these may not provide adequate relief for patients with severe disease. For those severely affected by AR, disease-modifying immunotherapy (IT) can be a valuable option. IT is currently the only treatment for AR that provides relief long after discontinuation of therapy. 4, 5 Historically, IT has been administered via subcutaneous injections (SCIT), but this delivery route carries a risk of systemic reactions, including anaphylaxis and rare fatalities. 6 Due to these concerns, SCIT is limited to the office setting, with frequent office visits, particularly in the induction phase, and with postinjection observation periods of up to 1 hour. 7 This commitment is often impractical for individuals with demanding schedules or those who do not live in close proximity to an SCIT provider. Furthermore, this route of delivery can be associated with discomfort from local reactions and fear of needles, which leads SCIT to be an unappealing choice for many adults and children.
There has been strong interest in developing alternative delivery methods for IT. In Europe, sublingual IT (SLIT) has become a common method of delivering IT and now accounts for 45% of all IT provided, with even higher rates of use in southern Europe. 8 Results of studies showed that SLIT improves AR symptoms, decreases use of medications, and improves respiratory symptoms in individuals with asthma. 9 SLIT provides an improved safety profile, with no history of fatal reactions, 10 and can reduce symptoms even when targeting only one or two allergens. 11 However, despite strong evidence that demonstrates the efficacy of SLIT, few comparative studies between SLIT and SCIT exist. Those available have shown SLIT to be comparable with SCIT when examining symptoms and medication use. [12] [13] [14] [15] The goal of this study was to compare changes in QOL between SCIT and SLIT over time.
METHODS

Study Population
Approval for this study was obtained from the institutional review board of Weill Cornell Medical College, New York (protocol 0712009555). Inclusion criteria were age Ն18 years, a history of moderate-to-severe persistent AR that affected sleep or daily activities, immunoglobulin E (IgE) mediated sensitivity demonstrated by either skin testing or serum IgE analysis, and failure of adequate symptom control with environmental control strategies and pharmacotherapy. Individuals with a history of previous IT were excluded from the study. Individuals who present to the outpatient otolaryngology department of Weill Cornell Medical College, who were scheduled to begin either SCIT or SLIT between January 1, 2009, and December 31, 2013, were approached to participate in the study. Those who agreed consented to chart review, IT treatment, and use of RQLQ data. The
participants were not randomized; they were offered the choice between SCIT and SLIT, and chose their IT method after extensive counseling on the risks, limitations, and benefits of each option.
IT
The participants who received SCIT were seen in the office weekly for the first year, and the dose was escalated to the maximum tolerated point before beginning the maintenance phase of therapy. For 8 of 11 of the participants who received SLIT (73%), a 10-day escalation period was used, with a daily dose of 0.02 mL of concentrated extract per allergen. The remaining three participants who received SLIT (27%) underwent a 12-week escalation schedule with a daily dose of 0.008 mL of concentrated extract per allergen. Both participants on SCIT and participants on SLIT underwent multiple allergen therapy based on the clinically relevant allergens to which they were sensitized, determined by IgE or skin testing. Concentrates were sourced from Greer Laboratories, Inc. (Lenoir, NC), Antigen Laboratories (Liberty, MO), and Hollister-Stier (Spokane, WA). The patients were treated based on current recommendations at the time 16, 17 of treatment, with the number of allergens used ranging from 5 to 9 in the SLIT group and 2 to 18 in the SCIT group.
QOL Survey
The Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) was used to measure QOL at different time points during treatment. Measured domains included sleep, practical functioning, non-nasal/ eye symptoms, nasal symptoms, eye symptoms, and emotional functioning. Overall, RQLQ was calculated as an average of all the responses within each domain previously mentioned. Each item was rated on a scale of 0 to 6 (0, not troubled; 6, extremely troubled). QOL was measured before the initiation of therapy (baseline), at 6 months into therapy, and at 1 year into therapy. The participants filled out these questionnaires at home and returned them by mail or filled them out at their office visit if it was at the appropriate time period.
Chart Review
For further data analysis, the charts of the participants were reviewed for sex, age, and asthma history. Asthma history was established based on previous clinical diagnosis by a primary care physician or pulmonologist and on medication history. The participants were not categorized based on the severity of their asthma because sufficient data were not available for all the participants. The participants were also divided into two age groups for analysis based on the median age of the participants: those Ͻ35 years of age and those Ն35 years of age at initiation of treatment. The age of the participants ranged from 22 to 74 years in the SLIT group and 24 to 64 years in the SCIT group.
Statistical Analysis
Data are presented as mean Ϯ standard deviation. RQLQ scores over time were analyzed by using analysis of variance (ANOVA), followed by two-tailed Student's t-tests for pairwise comparisons between baseline to 6-month and baseline to 1-year scores. Subgroup analysis of age, sex, and asthma history, in addition, was assessed by using ANOVA and pairwise comparisons with Student's t-testing. Fisher exact probability testing was used to test for the association between treatment group and the variables of age, asthma, and sex. Two-tailed p values were calculated by using Microsoft Office Excel 2010 for Windows (Microsoft Corporation, Redmond, WA) for the ANOVA and t-tests and online statistical software 18 for the Fisher exact probability testing. A value of p Ͻ 0.05 was considered statistically significant. A minimally important difference (MID) of 0.5 for the overall RQLQ score was used in our analysis, based on Juniper et al. 19 
RESULTS
Study Population
Of the 105 enrolled participants, 29 of 61 in the SCIT group (48%) and 11 of 44 in the SLIT group (25%) had data sufficient for analysis. All 105 initially enrolled patients completed and returned baseline RQLQ, to investigators, 59 completed and returned a 6-month RQLQ, and 42 completed and returned a 1-year RQLQ. The participants who successfully completed and returned an RQLQ for all three time points were included in the analysis. Ten participants in the SCIT group and one participant in the SLIT group were excluded from analysis due to incomplete sections of the RQLQ, which prevented calculation of overall and domain scores. The demographic characteristics of those 40 participants are presented in Table 1 . There was no significant difference (p ϭ 0.48) in age at initiation of treatment between the SCIT and SLIT groups. There was also no significant difference in the incidence of asthma compared between each group (p ϭ 0.14) or the distribution of sex within each group (p ϭ 0.72). Of note, an initial analysis was carried out for the larger group of participants who had complete data for baseline and 6 months, only in addition to those with complete data, and there was no notable change in statistically significant findings between SLIT and SCIT compared with the 1-year data.
Overall RQLQ Analysis
There was no significant difference in the baseline overall RQLQ score or any specific domain scores between the participants in the SCIT and SLIT groups. There was also no significant difference between 6-month SCIT and SLIT scores or between 1-year SCIT and SLIT scores overall or in the specific domains. The mean RQLQ scores over time can be seen in Fig. 1 A for the SCIT group and Fig. 1 B for the SLIT group. For patients on SCIT, the overall RQLQ score decreased by 29% from baseline to 1 year, whereas the overall RQLQ in the SLIT group decreased by 28% from baseline to 1 year.
The participants who underwent SCIT had significantly decreased overall RQLQ scores from baseline to 6 months (p ϭ 0.002) and from baseline to 1 year (p ϭ 0.002). The participants in the SCIT group also There was no statistically significant improvement in eye symptoms over the course of the study. The MID in the overall RQLQ score was achieved at both 6 months and 1 year of SCIT compared with baseline, and the MID was also met in multiple domains, which are indicated in Table 2 .
The participants who underwent SLIT treatment had a nonstatistically significant improvement in overall RQLQ score from baseline to 6 months and from baseline to 1 year of treatment. There also was a nonstatistically significant improvement in the specific domains scores from baseline to 6 months and from baseline to 1 year of treatment. There was an improvement in practical functioning scores of the SLIT group from baseline to 1 year that approached but did not achieve significance (p ϭ 0.055) with a mean difference of 1.1 in the RQLQ score. MID in the RQLQ score was achieved after 6 months and 1 year of SLIT treatment in the domain of practical functioning. MID was also achieved after 1 year of SLIT treatment in the overall RQLQ score and in the domains of nasal symptoms and emotional functioning. RQLQ scores for patients who underwent SLIT are shown in Table 2 .
Effects of Age
A significant improvement in the overall RQLQ score was seen after 6 months of treatment (p ϭ 0.038) and after 1 year of treatment (p ϭ 0.034) in participants in the SCIT group Ͻ35 years of age but not in those Ն35 years. In the participants in the SCIT group, Ն35 years and significant improvement was seen in the domain of sleep at 6 months (p ϭ 0.041) and 1 year (p ϭ 0.015) but was not seen in those Ͻ35 years. No significant difference was seen for the participants in the SCIT group in either age subgroup at 6 months or 1 year of treatment in the domains of non-nasal/eye symptoms, eye symptoms, practical functioning, or emotional functioning. In the domain of nasal symptoms, the participants in the SCIT group who were Ͻ35 years of age showed significant improvement after 6 months (p ϭ 0.004) and 1 year (p ϭ 0.007) of treatment, but participants Ն 35 years of age only had significant improvement after 1 year of treatment (p ϭ 0.044). No statistically significant changes overall or in domain scores were noted in the SLIT group for either age group. The change in overall RQLQ score in patients in the SLIT group and those in the SCIT group grouped by age can be seen in Fig. 2 A.
Effects of Asthma
The participants with a history of asthma in the SCIT group showed improvement in the overall RQLQ (p ϭ 0.002), sleep (p ϭ 0.008), practical functioning (p ϭ 0.037), and emotional functioning (p ϭ 0.035) scores after 6 months of treatment but not after 1 year compared with baseline. The participants in the SCIT group who had a history of asthma also showed significant improvement in the domain of nasal symptoms after 6 months of treatment (p ϭ 0.003) and 1 year of treatment (p ϭ 0.034). No significant improvement was seen in the domains of non-nasal/eye symptoms for SCIT subgroup analysis of both participants with or without a history of asthma. The participants on SCIT and without a history of asthma also showed no significant improvement in practical functioning. The SCIT group without asthma had improvement in the overall RQLQ score (p ϭ 0.055) and the domains of sleep (p ϭ 0.031), nasal symptoms (p ϭ 0.021), and emotional functioning (p ϭ 0.040) after 1 year of treatment but not at 6 months. Participants with a history of asthma who received SLIT showed significant improvement in the domains of nasal symptoms (p ϭ 0.017) and practical functioning (p ϭ 0.015) at 1 year but not at 6 months. No other significant improvements in RQLQ scores were seen at either time point in either subgroup of participants in the SLIT group with or without an asthma history. A change in the overall RQLQ score in patients in the SCIT group and patients in the SLIT group divided by asthma history is shown in Fig. 2 B. 
Figure 2. (A) A bar graph that compares overall Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores to baseline at 6 months and at 1 year of treatment in the participants in the sublingual immunotherapy (SLIT) group and in the participants in the subcutaneous immunotherapy (SCIT) group divided by age; *p Ͻ 0.05. (B) A bar graph that compares overall RQLQ scores to baseline at 6 months and at 1 year of treatment in the participants in the SLIT and in the SCIT groups divided by asthma history; *p Ͻ 0.05. (C) A bar graph that compares overall RQLQ scores to baseline at 6 months and at 1 year of treatment in participants in the SLIT group and in participants in
Effects of Sex
Female participants who received SCIT had significant improvement in overall RQLQ scores and the domains of sleep and nasal symptoms after 6 months of therapy (p Ͻ 0.05) and 1 year of therapy (p Ͻ 0.05); however, the female participants in the SCIT group had no significant change in the domains of practical functioning, non-nasal/ eye symptoms, eye symptoms, or emotional functioning. Male participants who received SCIT had significant improvement in overall RQLQ scores and nasal symptoms after 6 months (p Ͻ 0.05) and 1 year of treatment (p Ͻ 0.05). Male participants who were on SCIT also showed significant improvement in emotional functioning after 1 year of treatment (p ϭ 0.027) but not after 6 months and improvement in non-nasal/eye symptoms after 6 months of treatment (p ϭ 0.004) but not after 1 year. No significant improvement was seen in the domains of sleep or practical functioning for male participants in the SCIT group.
As a subgroup, the female participants who received SLIT showed no significant change in overall RQLQ score or any of the RQLQ domains measured. Male participants who received SLIT as a subgroup showed significant improvement in non-nasal/eye symptoms after 6 months of SLIT (p ϭ 0.049) but not after 1 year. The male participants in the SLIT group also had improvement at 6 months in the domain of eye symptoms, which approached but did not achieve statistical significance (p ϭ 0.058). The change in the overall RQLQ score in patients on SLIT and patients on SCIT divided by sex is shown in Fig. 2 C. 
DISCUSSION
Our findings that both SCIT and SLIT improved QOL were consistent with previous studies when using the RQLQ. Walker et al. 20 previously demonstrated improvements in the overall RQLQ scores and the scores in domains of non-nasal/eye symptoms, nasal symptoms, eye symptoms, emotional functioning, and activity in patients who received SCIT. Fell et al. 21 demonstrated significant improvement in energy level, emotional functioning, and social functioning in patients who received SCIT within 4-6 months of initiating SCIT treatment. Nelson et al. 22 demonstrated significant improvement in ocular, nasal, and overall RQLQ scores by using the tablet formulation of grass allergen. In addition, our study found QOL improvements in the domains of sleep and practical functioning not previously seen. More recent studies also demonstrated that SCIT can decrease the number of sick days taken by patients. 23 Interestingly, QOL improvement in patients in SCIT has not been consistently found in studies when using measurement parameters other than the RQLQ. Khinchi et al. 13 found no improvement in QOL in patients who underwent SCIT for 3 years by using the 36-Item Short Form Health Survey (SF-36). The RQLQ focuses on specific symptoms and aspects of AR, whereas the SF-36 looks more generally at QOL, which may account for these findings.
The results of our study also indicated that patient characteristics may influence QOL improvement during IT. We found that participants who initiated SCIT in the younger age group improved significantly compared with their older counterparts, which did not have statistically significant improvement as a subgroup. This does not mean that these older participants did not see a benefit from SCIT because significance may have been lost due to decreased power in the subgroup analysis and the older group scores did decrease, but this may indicate that younger patients derive more benefit from treatment. These results were consistent with previous evidence that demonstrated increased efficacy in IT when initiated at a younger age, likely due to less sensitization before initiating therapy, 24 although previous evidence has mainly been shown in children rather than adults. Early evidence also indicated that IT may be more cost effective than pharmacotherapy in the long term. 25 Given these findings, clinicians should ensure that they discuss IT as a treatment option with patients in a timely manner, especially in patients who show possible interest in disease-modifying therapy.
The participants who received SLIT demonstrated a nonstatistically significant improvement in overall QOL, and specific QOL domains with significant improvement in male participants in the domain of non-nasal/eye symptoms and participants with a history of asthma in the domains of nasal symptoms and practical functioning. We were not aware of any previous evidence that indicated that IT is more effective in one sex over the other. Existing evidence on sex as a predictive factor in adherence to IT is mixed, with male children seeming to have higher rates of adherence to IT, 26 whereas men ages 16-25 years have higher rates of withdrawal from treatment compared with their female peers. 27 The participants in our SCIT group also demonstrated variation in domains of improvement based on sex: the women improved in nasal symptoms and sleep, and the men improved in emotional functioning. Although both sexes clearly benefited from IT, it seemed that there may be variation in the magnitude of improvement in certain aspects of QOL.
Consistent with our findings, previous studies show patients with a history of asthma do have particular benefit from IT over patients without asthma, with IT improving specific respiratory symptoms in addition to rhinoconjunctivitis symptoms. 14, [28] [29] [30] IT was also shown to decrease the development of asthma in patients with rhinoconjunctivitis. 31 Clinicians should take care to enquire about patient's respiratory histories and maintain a low threshold for discussing IT with patients with a history of asthma. SLIT may actually confer an advantage over SCIT in this patient population, offering less risk of severe adverse effects, particularly in patients with poorly controlled asthma. 32 Contributing to the nonstatistically significant improvement of scores of patients in the SLIT group was the difference in the final group sizes secondary to the higher dropout rate in the SLIT group. In addition to the factor of power, previous studies also had mixed results regarding QOL in the patients in the SLIT group, despite numerous studies 7-9 that demonstrate efficacy. Rak et al. 33 found significant improvement in the overall RQLQ score of the patients on SLIT compared with a placebo group and found that QOL was improved more in patients taking SLIT alone than in those taking loratadine without IT. In contrast Khinchi et al. 13 showed no improvement in QOL in patients in SLIT over 3 years when using the SF-36, and Roder et al. 34 found no improvement in QOL when using the RQLQ in children who took SLIT for 2 years. Variability in antigen dosing may also play a role in inconsistent results in SLIT outcomes because dosing can vary between extract manufacturers and the regimen followed, which leads to potential underdosing compared with SCIT. 35 Another aspect of this study that may have affected QOL and our results was the lack of medication-use tracking throughout the study.
D O N O T C O P Y
Mungen et al. 14 and Rolinck-Werninhaus et al. 36 found that, although medication use decreased with SLIT, symptoms remained the same. It is possible that participants in the SLIT group did not have significant improvement in QOL because they were concurrently decreasing their use of symptom-controlling medications such as nasal steroids and antihistamines. It should also be noted that there was a high rate of dropout in both groups in our study, with only 48% of initially enrolled patients in SCIT and 27% of initially enrolled patients in the SLIT group who returned all three RQLQs over 1 year. Despite this high dropout rate, 64% of the dropouts in the SLIT group continued therapy and 50% of the dropouts in SCIT continued therapy after submitting their last RQLQ, which indicated that withdrawal was more likely due to the inconvenience of questionnaires rather than adverse effects from the treatment itself in those cases. Although questionnaires for the SCIT group were often completed while the patient was in the office, questionnaires for the SLIT group were more often mailed to patients to be completed and mailed back, and this may have presented an excessive barrier to completion and submission of the questionnaires. Of the patients who withdrew from treatment, the reasons cited included a change in treatment provider, local oral mucosal reactions, and perceived inefficacy. The higher dropout rate in the SLIT group may have influenced our findings because QOL may have been lower in those who chose to leave the study, which would not be reflected in our results.
Another possible reason for the nonstatistically significant improvement in QOL in the participants in the SLIT group may be adherence of the study population. Because SLIT is self-administered, there is the potential for multiple forms of nonadherence, which range from incorrect dosing to complete cessation of therapy. 37 Although the participants picked up refills of allergen extracts on a regularly scheduled basis, we did not use additional means to measure adherence, such as weighing the remaining allergen extracts at defined time periods or pill counting. 34 The reasons previously reported for poor adherence in patients in the SLIT group have been reactions to extracts, confusion regarding dosing 38, 39 and inconvenience. 40, 41 Discontinuation rates reported by manufacturers are Ͼ50% during the first year. 42 It is also notable that the participants were not randomized to treatment arms and that some participants may have specifically selected SLIT because of their concerns over adhering to the strict schedule of SCIT. Prescribing clinicians should consider adherence challenges when prescribing SLIT, particularly in patients on therapy whose symptoms seemed surprisingly recalcitrant to previously prescribed therapies.
CONCLUSION
Our study demonstrated a meaningful clinical improvement in QOL for both patients in the SCIT group and patients in the SLIT group in a "real-world" clinical setting, although who only achieved statistical significance in the SCIT group. Our study also supported previous evidence that indicated that patients who start IT at a younger age and those with a history of asthma are conferred a greater benefit from treatment than older patients and those without a history of asthma. Higher-powered and longer-term studies will be useful for further exploration of QOL effects of IT given that it is a long-term intervention with effects thought to last beyond our targeted study period. 
